Trial Outcomes & Findings for Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma (NCT NCT00703664)

NCT ID: NCT00703664

Last Updated: 2018-08-07

Results Overview

ORR: Complete Response (CR) + Partial Response (PR) assessed according to the Revised Response Criteria for Malignant Lymphoma.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 65 participants
• Primary outcome timeframe: Up to 9 years
• Results posted on: 2018-08-07

Participant Flow

Participants were enrolled at 12 participating cancer center sites in the United States, from July 2008 through December 2013.

Participant milestones

Measure	Treatment: Cohort A - MCL; No Prior Bortezomib Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib). Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.	Treatment: Cohort B - MCL; Prior Bortezomib Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib). Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.	Treatment: Cohort C - DLBCL; No Prior Bortezomib Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib). Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.
Overall Study STARTED	22	4	39
Overall Study COMPLETED	22	4	39
Overall Study NOT COMPLETED	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

Baseline characteristics by cohort

Measure	Treatment: Cohort A - MCL; No Prior Bortezomib n=22 Participants Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib). Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.	Treatment: Cohort B - MCL; Prior Bortezomib n=4 Participants Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib). Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.	Treatment: Cohort C - DLBCL; No Prior Bortezomib n=39 Participants Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib). Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.	Total n=65 Participants Total of all reporting groups
Age, Continuous	64 years n=93 Participants	63 years n=4 Participants	57 years n=27 Participants	60 years n=483 Participants
Sex: Female, Male Female	5 Participants n=93 Participants	0 Participants n=4 Participants	13 Participants n=27 Participants	18 Participants n=483 Participants
Sex: Female, Male Male	17 Participants n=93 Participants	4 Participants n=4 Participants	26 Participants n=27 Participants	47 Participants n=483 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants
Race (NIH/OMB) Asian	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants
Race (NIH/OMB) Black or African American	2 Participants n=93 Participants	0 Participants n=4 Participants	5 Participants n=27 Participants	7 Participants n=483 Participants
Race (NIH/OMB) White	19 Participants n=93 Participants	4 Participants n=4 Participants	30 Participants n=27 Participants	53 Participants n=483 Participants
Race (NIH/OMB) More than one race	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=93 Participants	0 Participants n=4 Participants	4 Participants n=27 Participants	5 Participants n=483 Participants
Region of Enrollment United States	22 Participants n=93 Participants	4 Participants n=4 Participants	39 Participants n=27 Participants	65 Participants n=483 Participants
Eastern Cooperative Oncology Group (ECOG) Status Status: 0	13 Participants n=93 Participants	3 Participants n=4 Participants	11 Participants n=27 Participants	27 Participants n=483 Participants
Eastern Cooperative Oncology Group (ECOG) Status Status: 1	9 Participants n=93 Participants	1 Participants n=4 Participants	19 Participants n=27 Participants	29 Participants n=483 Participants
Eastern Cooperative Oncology Group (ECOG) Status Status: 2	0 Participants n=93 Participants	0 Participants n=4 Participants	9 Participants n=27 Participants	9 Participants n=483 Participants

PRIMARY outcome

Timeframe: Up to 9 years

Population: All participants.

ORR: Complete Response (CR) + Partial Response (PR) assessed according to the Revised Response Criteria for Malignant Lymphoma.

Outcome measures

Measure	Cohort A - MCL n=22 Participants Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib).	Cohort B - MCL n=4 Participants Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib).	Cohort C - DLBCL n=39 Participants Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib).
Overall Response Rate (ORR)	31.8 percentage of participants	0 percentage of participants	7.7 percentage of participants

SECONDARY outcome

Timeframe: Up to 9 years

Population: All participants evaluable and available at time of assessment.

Number of participants per category: Partial Response (PR), Stable Disease (SD), Progressive Disease (PD). PR: Regression of measurable disease and no new sites. SD: Failure to attain Complete Response (CR), /PR or PD. Relapsed or Progressive Disease: Any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Outcome measures

Measure	Cohort A - MCL n=19 Participants Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib).	Cohort B - MCL n=4 Participants Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib).	Cohort C - DLBCL n=34 Participants Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib).
Best Response Partial Response	7 Participants	0 Participants	3 Participants
Best Response Stable Disease	5 Participants	2 Participants	8 Participants
Best Response Progressive Disease	7 Participants	2 Participants	23 Participants

SECONDARY outcome

Timeframe: Up to 9 years

Population: All evaluable participants at time of analysis. Cohort B was closed early due to lack of accrual.

Median progression-free survival in months per cohort.

Outcome measures

Measure	Cohort A - MCL n=22 Participants Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib).	Cohort B - MCL Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib).	Cohort C - DLBCL n=39 Participants Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib).
Progression-free Survival (PFS)	7.6 months Interval 2.2 to not reached	—	1.8 months Interval 1.4 to 2.3

SECONDARY outcome

Timeframe: Up to 9 years

Population: All participants with Partial Response.

Median duration of response per cohort.

Outcome measures

Measure	Cohort A - MCL n=7 Participants Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib).	Cohort B - MCL Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib).	Cohort C - DLBCL n=3 Participants Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib).
Duration of Partial Response	4.2 months Interval 0.13 to 16.9	—	2.1 months Interval 1.34 to 2.13

SECONDARY outcome

Timeframe: Up to 9 years

Population: All participants with stable disease.

Median duration of stable disease per cohort.

Outcome measures

Measure	Cohort A - MCL n=5 Participants Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib).	Cohort B - MCL n=2 Participants Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib).	Cohort C - DLBCL n=8 Participants Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib).
Duration of Stable Disease	3.8 months Interval 0.3 to 13.4	3.8 months Interval 3.5 to 4.0	1.3 months Interval 0.03 to 6.97

Adverse Events

Cohort A - MCL

Serious events: 9 serious events

Other events: 22 other events

Deaths: 0 deaths

Cohort B - MCL

Serious events: 1 serious events

Other events: 4 other events

Deaths: 0 deaths

Cohort C - DLBCL

Serious events: 22 serious events

Other events: 39 other events

Deaths: 4 deaths

Serious adverse events

Measure	Cohort A - MCL n=22 participants at risk Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib).	Cohort B - MCL n=4 participants at risk Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib).	Cohort C - DLBCL n=39 participants at risk Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib).
General disorders Multi-organ failure - Death	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasms benign, malignant and unspecified - Death	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Multi-organ failure	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Blood and lymphatic system disorders Anemia	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Cardiac disorders Myocardial infarction	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Cardiac disorders Sinus bradycardia	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Cardiac disorders Sinus tachycardia	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Cardiac disorders Ventricular arrhythmia	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Eye disorders Dry Eye	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Eye disorders Eye disorders - Other, Chalazion	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Abdominal pain	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Diarrhea	13.6% 3/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Gastritis	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Gastrointestinal disorders - Other, Duodenitis	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Gastrointestinal disorders - Other, Cramping	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Lower gastrointestinal hemorrhage	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Nausea	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Vomiting	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Chills	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Edema limbs	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Fatigue	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Fever	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Non-cardiac chest pain	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Pain	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Appendicitis	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Infectionsand infestations - Other	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Skin infection	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Wound infection	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Creatinine increased	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Ejection fraction decreased	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Electrocardiogram QT corrected interval prolonged	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Neutrophil count decreased	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Platelet count decreased	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 7 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Dehydration	9.1% 2/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypercalcemia	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypokalemia	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hyponatremia	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumor pain	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Dizziness	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Headache	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Nervous system disorders - Other	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Peripheral sensory neuropathy	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Syncope	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Psychiatric disorders Confusion	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Renal and urinary disorders Acute kidney injury	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Renal and urinary disorders Urinary incontinence	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Adult respiratory distress syndrome	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Hypoxia	4.5% 1/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Pneumonitis	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Vascular disorders Hypotension	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Vascular disorders Thromboembolic event	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.

Other adverse events

Measure	Cohort A - MCL n=22 participants at risk Mantle Cell Lymphoma (MCL): Treatment (vorinostat, bortezomib).	Cohort B - MCL n=4 participants at risk Mantle Cell Lymphoma MCL: Treatment (vorinostat, bortezomib).	Cohort C - DLBCL n=39 participants at risk Diffuse Large B-Cell Lymphoma (DLBCL): Treatment (vorinostat, bortezomib).
Gastrointestinal disorders Diarrhea	90.9% 20/22 • Number of events 54 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	50.0% 2/4 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	61.5% 24/39 • Number of events 46 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Nausea	63.6% 14/22 • Number of events 33 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	50.0% 2/4 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	51.3% 20/39 • Number of events 47 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Vomiting	45.5% 10/22 • Number of events 16 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	35.9% 14/39 • Number of events 24 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Constipation	31.8% 7/22 • Number of events 8 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	30.8% 12/39 • Number of events 15 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Abdominal pain	22.7% 5/22 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.6% 10/39 • Number of events 12 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Dyspepsia	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	12.8% 5/39 • Number of events 5 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Flatulence	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Stomach pain	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Abdominal distension	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Dry mouth	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Gastrointestinal disorders - Other, specify	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Lower gastrointestinal hemorrhage	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Dysphagia	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Gastrointestinal pain	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Gastroparesis	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Ileus	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Mucositis oral	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Gastrointestinal disorders Oral pain	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Platelet count decreased	81.8% 18/22 • Number of events 126 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	75.0% 3/4 • Number of events 5 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	66.7% 26/39 • Number of events 141 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Lymphocyte count decreased	50.0% 11/22 • Number of events 30 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	51.3% 20/39 • Number of events 65 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations White blood cell decreased	59.1% 13/22 • Number of events 32 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	35.9% 14/39 • Number of events 65 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Neutrophil count decreased	45.5% 10/22 • Number of events 19 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	30.8% 12/39 • Number of events 32 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Creatinine increased	31.8% 7/22 • Number of events 19 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	30.8% 12/39 • Number of events 42 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Aspartate aminotransferase increased	13.6% 3/22 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	17.9% 7/39 • Number of events 10 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Alanine aminotransferase increased	13.6% 3/22 • Number of events 5 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	12.8% 5/39 • Number of events 9 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Alkaline phosphatase increased	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 8 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Electrocardiogram QT corrected interval prolonged	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Weight loss	13.6% 3/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Investigations - Other, specify	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations INR increased	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Weight gain	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Activated partial thromboplastin time prolonged	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Blood bilirubin increased	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Cardiac troponin T increased	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations Cholesterol high	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Investigations CPK increased	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Anorexia	50.0% 11/22 • Number of events 11 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	38.5% 15/39 • Number of events 23 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hyperglycemia	22.7% 5/22 • Number of events 7 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	75.0% 3/4 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	35.9% 14/39 • Number of events 25 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hyponatremia	22.7% 5/22 • Number of events 14 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	28.2% 11/39 • Number of events 15 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypocalcemia	22.7% 5/22 • Number of events 11 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.6% 10/39 • Number of events 17 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Dehydration	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	10.3% 4/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypoalbuminemia	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	23.1% 9/39 • Number of events 12 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypokalemia	13.6% 3/22 • Number of events 5 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 17 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypoglycemia	9.1% 2/22 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 15 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypomagnesemia	9.1% 2/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 9 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypercalcemia	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hyperkalemia	13.6% 3/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hypophosphatemia	4.5% 1/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Acidosis	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Metabolism and nutrition disorders Hyperuricemia	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Fatigue	81.8% 18/22 • Number of events 39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	56.4% 22/39 • Number of events 48 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Chills	31.8% 7/22 • Number of events 10 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Edema limbs	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	12.8% 5/39 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Fever	9.1% 2/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 9 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Pain	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 7 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Malaise	9.1% 2/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Non-cardiac chest pain	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Edema trunk	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Facial pain	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
General disorders Irritability	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Peripheral sensory neuropathy	45.5% 10/22 • Number of events 20 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.6% 10/39 • Number of events 12 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Dizziness	54.5% 12/22 • Number of events 16 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	17.9% 7/39 • Number of events 7 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Headache	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	28.2% 11/39 • Number of events 15 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Dysgeusia	13.6% 3/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Paresthesia	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Peripheral motor neuropathy	4.5% 1/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Nervous system disorders - Other, specify	4.5% 1/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Syncope	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Nervous system disorders Cognitive disturbance	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Blood and lymphatic system disorders Anemia	31.8% 7/22 • Number of events 26 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	51.3% 20/39 • Number of events 70 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Blood and lymphatic system disorders Blood and lymphatic system disorders - Other, specify	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Blood and lymphatic system disorders Hemolysis	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Blood and lymphatic system disorders Thrombotic thrombocytopenic purpura	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Back pain	13.6% 3/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	15.4% 6/39 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Pain in extremity	22.7% 5/22 • Number of events 8 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Generalized muscle weakness	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	10.3% 4/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Myalgia	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Neck pain	13.6% 3/22 • Number of events 5 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Arthralgia	4.5% 1/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Flank pain	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Bone pain	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Joint range of motion decreased	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Muscle weakness lower limb	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Musculoskeletal and connective tissue disorders Muscle weakness upper limb	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Dyspnea	13.6% 3/22 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	30.8% 12/39 • Number of events 15 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Cough	9.1% 2/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	50.0% 2/4 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	17.9% 7/39 • Number of events 8 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Nasal congestion	4.5% 1/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Productive cough	4.5% 1/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Allergic rhinitis	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Bronchopulmonary hemorrhage	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Respiratory, thoracic and mediastinal disorders Sore throat	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Pruritus	9.1% 2/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	10.3% 4/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Skin and subcutaneous tissue disorders - Other, specify	13.6% 3/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Rash maculo-papular	9.1% 2/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Hyperhidrosis	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Alopecia	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Rash acneiform	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Dry skin	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysesthesia syndrome	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Periorbital edema	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Purpura	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Scalp pain	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Skin and subcutaneous tissue disorders Skin induration	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Infections and infestations - Other, specify	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Papulopustular rash	9.1% 2/22 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Sinusitis	4.5% 1/22 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Hepatitis viral	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Lung infection	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Mucosal infection	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Pharyngitis	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Sepsis	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Upper respiratory infection	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Urinary tract infection	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Infections and infestations Wound infection	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Psychiatric disorders Anxiety	18.2% 4/22 • Number of events 5 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	12.8% 5/39 • Number of events 6 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Psychiatric disorders Insomnia	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Psychiatric disorders Confusion	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Psychiatric disorders Depression	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Psychiatric disorders Agitation	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Psychiatric disorders Restlessness	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Vascular disorders Hypotension	13.6% 3/22 • Number of events 7 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	10.3% 4/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Vascular disorders Hypertension	9.1% 2/22 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Vascular disorders Thromboembolic event	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 3 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Vascular disorders Lymphedema	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Vascular disorders Vascular disorders - Other, specify	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Renal and urinary disorders Acute kidney injury	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Renal and urinary disorders Proteinuria	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Renal and urinary disorders Renal and urinary disorders - Other, specify	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Renal and urinary disorders Urinary frequency	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Renal and urinary disorders Urinary incontinence	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	5.1% 2/39 • Number of events 2 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Renal and urinary disorders Urinary tract pain	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Cardiac disorders Sinus tachycardia	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	7.7% 3/39 • Number of events 4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Cardiac disorders Sinus bradycardia	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Cardiac disorders Atrial fibrillation	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Eye disorders Dry eye	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Eye disorders Blurred vision	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Eye disorders Conjunctivitis	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Eye disorders Eye disorders - Other, specify	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Eye disorders Eyelid function disorder	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	25.0% 1/4 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Injury, poisoning and procedural complications Bruising	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Injury, poisoning and procedural complications Injury, poisoning and procedural complications - Other, specify	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Injury, poisoning and procedural complications Vascular access complication	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Injury, poisoning and procedural complications Wound dehiscence	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Ear and labyrinth disorders Hearing impaired	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Ear and labyrinth disorders Vertigo	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Immune system disorders Allergic reaction	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Immune system disorders Autoimmune disorder	0.00% 0/22 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	2.6% 1/39 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.
Hepatobiliary disorders Gallbladder fistula	4.5% 1/22 • Number of events 1 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/4 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.	0.00% 0/39 • 5 years NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was used for reporting adverse events until April 1, 2011, when mandatory conversion to CTCAE v4.0 supervened. Response was assessed using the Revised Response Criteria for Malignant Lymphoma.

Additional Information

Dr. Beata Holkova

Massey Cancer Center, Virginia Commonwealth University

Phone: 804-628-2581

Email: bholkova@mcvh-vcu.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place

Restriction type: LTE60